Immune Thrombocytopenia Following the Pfizer-BioNTech BNT162b2 mRNA COVID-19 Vaccine

Isr Med Assoc J. 2021 Jun;23(6):341.
No abstract available

Publication types

  • Case Reports

MeSH terms

  • BNT162 Vaccine
  • COVID-19 / prevention & control*
  • COVID-19 Vaccines* / administration & dosage
  • COVID-19 Vaccines* / adverse effects
  • Dexamethasone / administration & dosage*
  • Humans
  • Immunoglobulins, Intravenous / administration & dosage*
  • Immunologic Factors / administration & dosage
  • Male
  • Middle Aged
  • Platelet Count / methods*
  • Purpura* / diagnosis
  • Purpura* / etiology
  • Purpura, Thrombocytopenic, Idiopathic* / diagnosis
  • Purpura, Thrombocytopenic, Idiopathic* / etiology
  • Purpura, Thrombocytopenic, Idiopathic* / physiopathology
  • Purpura, Thrombocytopenic, Idiopathic* / therapy
  • SARS-CoV-2
  • Treatment Outcome
  • Viral Vaccines / administration & dosage
  • Viral Vaccines / adverse effects

Substances

  • COVID-19 Vaccines
  • Immunoglobulins, Intravenous
  • Immunologic Factors
  • Viral Vaccines
  • Dexamethasone
  • BNT162 Vaccine